NIKKEI 225
38,265.24 -8.81 (-0.02%) HANG SENG
17,998.64 +235.61 (+1.33%) CRUDE OIL
79.35 +0.35 (+0.44%) GOLD FUTURES
2,330.90 +19.90 (+0.86%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,671.33 -1,990.34 (-4.18%)
AstraZeneca PLC (ZEG.MU)
| Previous close | 141.35 |
| Open | 140.80 |
| Bid | 141.80 x 0 |
| Ask | 142.30 x 0 |
| Day's range | 140.80 - 140.80 |
| 52-week range | 113.00 - 141.35 |
| Volume | |
| Avg. volume | 42 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireAstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del., May 01, 2024--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA), as
Fool.co.uk£20,000 in cash? Here’s how I’d aim for £10,000 in annual passive income!
Our writer explains how he'd maximise his investment allowance in a Stocks and Shares ISA to target £10k in tax-free passive income every year. The post £20,000 in cash? Here’s how I’d aim for £10,000 in annual passive income! appeared first on The Motley Fool UK.
Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
WILMINGTON, Del., April 29, 2024--Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy.
